Skip to main content
. 2018 Oct 6;8(18):5106–5125. doi: 10.7150/thno.26585

Figure 10.

Figure 10

Morphologic analysis of the site of BT-474 tumor inoculation at 85 d shows that treatment with anti-HER2-DOTA-PRIT leads to cures (5/8) or microscopic residual disease (red arrows; 3/8), while controls (10/10) show bulk tumor present by H&E staining (please see Table S8 for detailed description). IHC analysis shows that all residual tumors are HER2 antigen positive.